Frontiers In Molecular Pharming

The advent of large-scale production and clinical trials of drugs developed through diverse production routes - involving viruses, microbes, plants, and animals - has increased the demand for an expanded capacity for pharmaceutical manufacturing. The production and purification of expressed proteins accounts for the bulk of the manufacturing costs for new therapeutics. Several pharmaceutical proteins have been synthesized by exploiting plant genetics allowing producers to override conventional approaches used to manufacture pharmaceuticals. The process of inserting a gene into a host organism for the purpose of harvesting a bioactive molecule for therapeutic use is known as molecular pharming. Frontiers in Molecular Pharming covers an array of topics relevant to understanding the structure, function, regulation, and mechanisms of action, biochemical significance, and usage of proteins and peptides as biomarkers, therapeutics, and vaccines for animals and humans. The contributions aim to highlight current progress in three areas, including system biology (in vivo characterization of proteins and peptides), molecular pharming for animals and molecular pharming for humans. The book gives special attention to computational biology tools, production platforms and fields (such as immunoinformatics) and applications of molecular pharming (such as veterinary therapeutics). A balance of theoretical concepts and practical applications is provided through 13 chapters. Frontiers in Molecular Pharming is an invaluable resource for students and researchers of biochemistry, molecular biology, and biotechnology. The book also serves as a springboard for understanding the process of how discoveries in protein and peptide research and its applications are coming to fruition.

The advent of large-scale production and clinical trials of drugs developed through diverse production routes - involving viruses, microbes, plants, and animals - has increased the demand for an expanded capacity for pharmaceutical manufacturing. The production and purification of expressed proteins accounts for the bulk of the manufacturing costs for new therapeutics. Several pharmaceutical proteins have been synthesized by exploiting plant genetics allowing producers to override conventional approaches used to manufacture pharmaceuticals. The process of inserting a gene into a host organism for the purpose of harvesting a bioactive molecule for therapeutic use is known as molecular pharming. Frontiers in Molecular Pharming covers an array of topics relevant to understanding the structure, function, regulation, and mechanisms of action, biochemical significance, and usage of proteins and peptides as biomarkers, therapeutics, and vaccines for animals and humans. The contributions aim to highlight current progress in three areas, including system biology (in vivo characterization of proteins and peptides), molecular pharming for animals and molecular pharming for humans. The book gives special attention to computational biology tools, production platforms and fields (such as immunoinformatics) and applications of molecular pharming (such as veterinary therapeutics). A balance of theoretical concepts and practical applications is provided through 13 chapters. Frontiers in Molecular Pharming is an invaluable resource for students and researchers of biochemistry, molecular biology, and biotechnology. The book also serves as a springboard for understanding the process of how discoveries in protein and peptide research and its applications are coming to fruition.

This eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact.

Infectious diseases are still a major threat to public health. The vaccine remains the most important and safer way of combating infectious diseases. Therefore, there is an urgent need to look for new ways of vaccine generation that can cut down production costs and processing time. The development of rDNA technology allows the expression and purification of proteins in unlimited quantity, thus opening an avenue for the development of protein-based vaccines as a prophylactic measure against infectious diseases. Recombinant therapeutic proteins derived from biological sources, including mammalian cells, microorganisms, suspension cultures, or genetically modified organisms by employing biotechnological processes, are widely used in clinical applications, especially for the treatment and prevention of human or veterinary infections. Since the development of human insulin by utilizing recombinant DNA technology in E. coli in the 1980s, the recombinant therapeutic protein production field has significantly grown and gained major attention. Plant molecular farming, the production of biologics in plant cells or transgenic plants, could offer a cost-effective adaptable strategy to produce biologics, particularly in low-resource settings. Molecular farming-based strategies could provide an alternative strategy to traditional biologics or vaccine production, enabling rapid development, effective deployment, and safe administration of vaccines. The concept of PMF was initially documented three decades back when recombinant growth hormone was produced in tobacco and sunflower plants. Even with such a long history of significant advantages and several proof-of-concept studies, very few plant-derived therapeutic products have been clinically translated. However, the recent progress around the approval of the plant-based biopharmaceutical ZMapp by the FDA, Medicago’s COVID-19 vaccine by Health Canada, and the safety of a few plant-derived vaccines in clinical trials have displayed the potential of a plant platform for biopharmaceutical production. Furthermore, constant efforts are being made with respect to the optimization of expression techniques, downstream processing, and defining standard guidelines for plant products to make an impact of plant-derived products on an array of applications.

Molecular farming is a biotechnological approach that includes the genetic adjustment of agricultural products to create proteins and chemicals for profitable and pharmaceutical purposes. Plant molecular farming describes the manufacture of recombinant proteins and other biologically active product in plants. This approach depends on a genetic transformation of plants that can be accomplished by the methods of stable gene transfer, such as gene transfer to nuclei and chloroplasts, and unstable transfer methods like viral vectors. The requirement for recombinant proteins in terms of quality, quantity, and diversity is increasing exponentially This demand is traditionally met by recombinant protein construction technologies and the engineering of orthodox expression systems based on bacteria or mammalian cell cultures. However, majority of developing countries cannot afford the high costs of medicine derived from such existing methods. Hence, we need to produce not only the new drugs but also the cheaper versions of those already present in the market. Plant molecular farming is considered as a cost-effective technology that has grown and advanced tremendously over the past two decades. This book summarizes the advances and challenges of plant molecular farming for all those who are working on or have an interest in this rapidly emerging area of research.

Plant Transformation via Agrobacterium Tumefaciens compiles fundamental and specific information and procedures involving in vitro soybean transformation, which forms the basis for the Agrobacterium-mediated genetic manipulation of soybean using plant tissue culture. This method serves as one of the most preferred, reliable and cost-effective mechanism of transgene expression in both leguminous recalcitrant species and non-legume crops. The technology is favoured due to its simplicity, feasibility and high transformation rates that are so far achieved mostly in monocot plants and a few dicot genotypes. This book provides a comprehensive review of plant transformation which remains necessary for many researchers who are still facing protocol-related hurdles. Among some of the major topics covered in Plant Transformation via Agrobacterium Tumefaciens are the history and discovery of Agrobacterium bacterium, longstanding challenges causing transformation inefficiencies, types and conditions of explants, development of transgenic plants for stress resistance, and the role of transgenic plants on animal/human health, including the environment. Plant Transformation via Agrobacterium Tumefaciens helps the reader to understand how soybean, like many other orphan legume crops, faces the risk of overexploitation which may render the currently available varieties redundant and extinct should its narrow gene pool not improve. Plant transformation serves as a key technique in improving the gene pool, while developing varieties that are drought tolerant, have enhanced nutritional value, pest resistant and reduce the destruction by disease causing microorganims. This book is an essential foundation tool that is available for researchers and students to reinforce the application of Agrobacterium-mediated genetic transformation in soybean.

Plant gene transfer achieved in the early ‘80s paved the way for the exploitation of the potential of gene engineering to add novel agronomic traits and/or to design plants as factories for high added value molecules. For this latter area of research, the term "Molecular Farming" was coined in reference to agricultural applications in that major crops like maize and tobacco were originally used basically for pharma applications. The concept of the “green biofactory” implies different advantages over the typical cell factories based on animal cell or microbial cultures already when considering the investment and managing costs of fermenters. Although yield, stability, and quality of the molecules may vary among different heterologous systems and plants are competitive on a case-to-case basis, still the “plant factory” attracts scientists and technologists for the challenging features of low production cost, product safety and easy scale up. Once engineered, a plant is among the cheapest and easiest eukaryotic system to be bred with simple know-how, using nutrients, water and light. Molecules that are currently being produced in plants vary from industrial and pharmaceutical proteins, including medical diagnostics proteins and vaccine antigens, to nutritional supplements such as vitamins, carbohydrates and biopolymers. Convergence among disciplines as distant as plant physiology and pharmacology and, more recently, as omic sciences, bioinformatics and nanotechnology, increases the options of research on the plant cell factory. “Farming for Pharming” biologics and small-molecule medicines is a challenging area of plant biotechnology that may break the limits of current standard production technologies. The recent success on Ebola fighting with plant-made antibodies put a spotlight on the enormous potential of next generation herbal medicines made especially in the name of the guiding principle of reduction of costs, hence reduction of disparities of health rights and as a tool to guarantee adequate health protection in developing countries.